Zacks Research Has Optimistic View of Immunovant Q3 Earnings
Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Research analysts at Zacks Research upped their Q3 2026 earnings per share estimates for shares of Immunovant in a research note issued on Thursday, December 18th. Zacks Research analyst Team now forecasts that the company will earn ($0.76) per share for the quarter, up from their previous estimate […]
23 Dec 01:15 · The Cerbat Gem